Dilafor AB, part of Karolinska Development’s portfolio of companies, has signed an agreement with Hong Kong-based biopharmaceutical firm.
According to the agreement, Dilafor grants to Lee’s Pharmaceutical the right to manufacture, develop and commercialize tafoxiparin for obstetrics and gynecological indications in China, Hong Kong, Macau and Taiwan. Pursuant to the terms of the agreement, Dilafor and Lee’s Pharmaceutical will jointly develop tafoxiparin for obstetrical and gynecological indications. The joint clinical development program of tafoxiparin will initially be focused on reducing labor times for patients who do not start labor spontaneously and are induced into labor.
“We are looking forward to working together with Lee’s Pharmaceutical and to take tafoxiparin into further clinical development”, says Lena Degling Wikingsson, CEO at Dilafor AB, in a press release.
Dilafor will receive an upfront payment as well as future development and sales milestones plus royalties on sales of the product which will be manufactured and sold by Lee’s Pharmaceutical in China, Hong Kong, Macau and Taiwan. Lee’s Pharmaceutical will conduct and finance Phase II and Phase III trials in China, so that the results can be used as the basis for additional development outside the countries where Lee’s Pharmaceutical has its license. Further details on the terms of the agreement are not being disclosed.
Photo: Dilafor CEO Lena Degling Wikingsson. Photo credit Eurocine Vaccines